| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 04/27/2000 | WO2000023086A2 Buffered compositions for dialysis |
| 04/27/2000 | WO2000023045A1 Pharmaceutical composition with gastric residence and controlled release |
| 04/27/2000 | WO2000022937A1 Protein material for slow digestion and its use |
| 04/27/2000 | WO1999063933A9 Multivalent agonists, partial agonists and antagonists of the gaba receptors |
| 04/27/2000 | DE19849044A1 New polycythemia rubra vera-related polypeptide useful for diagnosis and for developing therapeutic antibodies |
| 04/27/2000 | DE19845286A1 New carrier material coated with specific antibodies, used to remove tumor necrosis factor and other disease-associated compounds from blood, for treating arthritis or pyelonephritis |
| 04/27/2000 | CA2347625A1 Genes and proteins predictive and therapeutic for renal disease and associated disorders |
| 04/27/2000 | CA2347172A1 Protein material for slow digestion and its use |
| 04/27/2000 | CA2347080A1 Tnfr related gene 12 |
| 04/27/2000 | CA2346937A1 Specific therapeutic interventions obtained by interference with redistribution and/or targeting |
| 04/26/2000 | EP0995751A2 Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction |
| 04/26/2000 | EP0995750A1 Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction |
| 04/26/2000 | EP0994870A1 Novel aryloxy substituted pyrimidine imidazole compounds |
| 04/26/2000 | EP0994861A1 NEW $g(b)-AMINO AND $g(b)-AZIDOCARBOXYLIC ACID DERIVATIVES, THE PRODUCTION THEREOF AND THE USE THEREOF AS ENDOTHELIN RECEPTOR ANTAGONISTS |
| 04/26/2000 | EP0994711A1 Adenosine a1 receptor antagonist containing composition and method for restoring diuretic and rnal function |
| 04/26/2000 | EP0994708A1 Antagonists of gonadotropin releasing hormone |
| 04/26/2000 | EP0994705A1 Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides |
| 04/26/2000 | EP0771209A4 Novel peptides |
| 04/26/2000 | CN1251573A Solid composition suitable for oral administration comprising non hydroscopic salts of L-carnitine or alkanoyl-L-carnitine with 2-aminoethanesulfonic acid |
| 04/26/2000 | CN1251569A Noval compounds, their use and preparation |
| 04/26/2000 | CN1251527A Method of treating prostatic disease using delayed and/or sustained release vitamin D formulations |
| 04/26/2000 | CN1251311A Chinese medicine--Xinan Haubinia Championi |
| 04/25/2000 | US6054588 Heterocyclic vinyl ethers |
| 04/25/2000 | US6054560 Mitogen activated protein kinase, FRK |
| 04/25/2000 | US6054457 Benzamide derivatives and their use as vasopressin antagonists |
| 04/25/2000 | US6054432 Means for treating prostate hypertrophy and prostate cancer |
| 04/25/2000 | US6054308 Arginase II |
| 04/23/2000 | CA2287562A1 Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction |
| 04/21/2000 | CA2287122A1 Treatment of bph with cgmp elevators |
| 04/21/2000 | CA2251265A1 Process for lipid extraction of aquatic animal tissues producing a dehydrated residue |
| 04/20/2000 | WO2000022113A1 ENZYMATIC SYNTHESIS OF ssDNA |
| 04/20/2000 | WO2000021963A1 Il-8 receptor antagonists |
| 04/20/2000 | WO2000021955A1 Quinazoline derivatives |
| 04/20/2000 | WO2000021525A2 Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent |
| 04/20/2000 | WO2000021509A2 Methods of treatment |
| 04/20/2000 | WO1999066917A3 Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid |
| 04/20/2000 | WO1999064000A9 Novel therapeutic agents that modulate neurokinin receptors |
| 04/20/2000 | CA2346155A1 Enzymatic synthesis of ssdna |
| 04/19/2000 | EP0993449A1 Quinoline derivatives as pde iv and/or tnf inhibitors |
| 04/19/2000 | EP0880524B1 Adenosin antagonists, method of preparing them and their use as drugs |
| 04/19/2000 | CN1251021A 宠物食品组合物 Pet food composition |
| 04/19/2000 | CN1250666A Chinese medicine for treating prostatic disease and preparing process thereof |
| 04/18/2000 | US6051712 Piperidine derivatives having renin inhibiting activity |
| 04/18/2000 | US6051594 Orally administering a formulation of the vasodilator phentolamine to the blood circulation |
| 04/18/2000 | US6051555 Administering a peptide |
| 04/18/2000 | US6051400 An expression system comprising of a polynucleotide encoding a protein; therapy and diagnosis of kidney diseases, cardiovascular disorders, strokes, alzheimer's disease; anticarcinogenic agents and antiinflammatory agents |
| 04/18/2000 | US6051227 Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| 04/13/2000 | WO2000020621A1 Extracellular novel rage binding protein (en-rage) and uses thereof |
| 04/13/2000 | WO2000020458A1 Methods for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
| 04/13/2000 | WO2000020444A1 Novel peptides |
| 04/13/2000 | WO2000020443A1 Novel peptides |
| 04/13/2000 | WO2000020389A1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 04/13/2000 | WO2000020358A2 NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION |
| 04/13/2000 | WO2000020035A1 Oxybutynin formulations and methods of use |
| 04/13/2000 | WO2000020003A1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 04/13/2000 | WO2000002850A3 Sulfonylamino carboxylic acid n-arylamides as guanylate cyclase activators |
| 04/13/2000 | CA2346339A1 Methods for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
| 04/13/2000 | CA2346332A1 Oxybutynin formulations and methods of use |
| 04/13/2000 | CA2346217A1 Extracellular novel rage binding protein (en-rage) and uses thereof |
| 04/13/2000 | CA2345881A1 Bone marrow-derived serum proteins |
| 04/13/2000 | CA2345133A1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 04/13/2000 | CA2344807A1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 04/13/2000 | CA2344765A1 Novel peptides |
| 04/13/2000 | CA2344551A1 P-conotoxin peptide |
| 04/13/2000 | CA2341346A1 Non-peptide gnrh agents, methods and intermediates for their preparation |
| 04/12/2000 | EP0992584A2 Purified mammalian FLT3 ligands and agonists and antagonists thereof |
| 04/12/2000 | EP0992493A1 Substituted benzoylpiperidine derivatives and their use as Neurokinin antagonists |
| 04/12/2000 | EP0992243A1 Prophylactic/remedial agent |
| 04/12/2000 | EP0991758A1 Smad6 and uses thereof |
| 04/12/2000 | EP0991660A1 Deuterated cyclosporine analogs and their use as immunomodulating agents |
| 04/12/2000 | EP0991647A1 Eprosartan monohydrate |
| 04/12/2000 | EP0991424A1 Pharmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor |
| 04/11/2000 | US6048963 Polynucleotides and polypeptides associated with benign prostatic hypertrophy |
| 04/11/2000 | US6048897 Lipoxin compounds and their use in treating cell proliferative disorders |
| 04/11/2000 | US6048891 Administering mixtures with 6-hydroxy-2,7,8-trimethyl-chroman-2-propanoic acid for treatment of cardiovascular and kidney disorders |
| 04/11/2000 | US6048888 Method and pharmaceutical formulation for treating benign prostatic hyperplasia |
| 04/11/2000 | US6048869 Reductase inhibitors |
| 04/11/2000 | US6048864 Benign prostatic hyperplasia |
| 04/11/2000 | US6048859 Morpholine and thiomorpholine tachykinin receptor antagonists |
| 04/11/2000 | US6048523 Polyester cyclic compounds, their complexes and bonded bodies |
| 04/08/2000 | CA2285120A1 Heterocycles |
| 04/06/2000 | WO2000018919A1 Human kinesin-like motor protein |
| 04/06/2000 | WO2000018915A2 Membrane-associated organizational proteins |
| 04/06/2000 | WO2000018899A2 Angiotensin converting enzyme homolog and its use |
| 04/06/2000 | WO2000018895A1 Short peptides which selectively modulate the activity of protein kinases |
| 04/06/2000 | WO2000018801A2 Ncam binding compounds |
| 04/06/2000 | WO2000018761A1 Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
| 04/06/2000 | WO2000018744A1 Oxazole compounds as prostaglandin e2 agonists or antagonists |
| 04/06/2000 | WO2000018740A1 Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
| 04/06/2000 | WO2000018438A1 Dna encoding mammalian neuropeptide ff (npff) receptors and uses thereof |
| 04/06/2000 | WO2000018424A1 Use of substances with oxytocin activity in order to create cell regeneration |
| 04/06/2000 | WO2000018393A1 Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin |
| 04/06/2000 | WO2000018391A1 Drugs for improving vesical excretory strength |
| 04/06/2000 | WO2000018352A2 A method for treating inflammatory diseases by administering a thrombin inhibitor |
| 04/06/2000 | WO2000018212A2 Platelet-derived growth factor c, dna coding therefor, and uses thereof |
| 04/06/2000 | WO1999067384A3 Prostate cancer-associated genes |
| 04/06/2000 | WO1999054706A3 Method of treating interstitial cystitis with recombinant hb-egf |
| 04/06/2000 | CA2345641A1 A method for treating inflammatory diseases by administering a thrombin inhibitor |
| 04/06/2000 | CA2345474A1 Oxazole compounds as prostaglandin e2 agonists or antagonists |
| 04/06/2000 | CA2344894A1 Agents for improving excretory potency of urinary bladder |